Author(s): A. Sathish Kumar, P. Bhaskara Reddy

Email(s): sathishk0711@gmail.com

DOI: 10.52711/0974-360X.2024.00376   

Address: A. Sathish Kumar1*, P. Bhaskara Reddy2
1Associate Professor, Department of EEE, Holy Mary Institute of Technology and Science, Hyderabad, Telangana, India.
2Professor and Director, Department of Electronics and Communication Engineering, Holy Mary Institute of Technology and Science, Hyderabad, Telangana, India.
*Corresponding Author

Published In:   Volume - 17,      Issue - 5,     Year - 2024


ABSTRACT:
This article discusses the development of drugs for uncommon diseases as well as the future prospects for these drugs. When developing treatments for uncommon diseases, there are several challenges that must be overcome. Among them are limited patient populations, a lack of understanding of uncommon diseases, and regulatory hurdles. Regulatory incentives and advancements in drug development are discussed in addition to the use of biomarkers and repurposing existing drugs. Patients suffering from uncommon diseases need innovation and collaboration.


Cite this article:
A. Sathish Kumar, P. Bhaskara Reddy. A Review of The State of Drug Development for uncommon Diseases and its Future Potential. Research Journal of Pharmacy and Technology. 2024; 17(5):2405-8. doi: 10.52711/0974-360X.2024.00376

Cite(Electronic):
A. Sathish Kumar, P. Bhaskara Reddy. A Review of The State of Drug Development for uncommon Diseases and its Future Potential. Research Journal of Pharmacy and Technology. 2024; 17(5):2405-8. doi: 10.52711/0974-360X.2024.00376   Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2024-17-5-72


REFERENCES:
1.    Epps C, Bax R, Croker A, et al. Global Regulatory and Public Health Initiatives to Advance Pediatric Drug Development for Rare Diseases. Ther Innov Regul Sci. 2022; 56(6): 964-975. doi:10.1007/s43441-022-00409-w
2.    Miller KL, Fermaglich LJ, Maynard J. Using four decades of FDA orphan drug designations to describe trends in rare disease drug development: substantial growth seen in development of drugs for rare oncologic, neurologic, and pediatric-onset diseases. Orphanet J Rare Dis. 2021; 16(1). doi:10.1186/s13023-021-01901-6
3.    Pontes C, Fontanet JM, Vives R, et al. Evidence supporting regulatory-decision making on orphan medicinal products authorisation in Europe: Methodological uncertainties. Orphanet J Rare Dis. 2018; 13(1). doi:10.1186/s13023-018-0926-z
4.    Casamento K, Laverty A, Wilsher M, et al. Assessing the feasibility of a web-based registry for multiple orphan lung diseases: The Australasian Registry Network for Orphan Lung Disease (ARNOLD) experience. Orphanet J Rare Dis. 2016; 11(1). doi:10.1186/s13023-016-0389-z
5.    Gyawali B, Hey SP, Kesselheim AS. Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval. JAMA Intern Med. 2019; 179(7): 906-913. doi:10.1001/jamainternmed.2019.0462
6.    Song P, Gao J, Inagaki Y, Kokudo N, Tang W. Rare diseases, orphan drugs, and their regulation in Asia: Current status and future perspectives. Intractable Rare Dis Res. 2012; 1(1): 3-9. doi:10.5582/irdr.2012.v1.1.3
7.    Aartsma-Rus A, Dooms M, Le Cam Y. Orphan Medicine Incentives: How to Address the Unmet Needs of Rare Disease Patients by Optimizing the European Orphan Medicinal Product Landscape Guiding Principles and Policy Proposals by the European Expert Group for Orphan Drug Incentives (OD Expert Group). Front Pharmacol. 2021; 12. doi:10.3389/fphar.2021.744532
8.    Austin CP, Cutillo CM, Lau LPL, et al. Future of Rare Diseases Research 2017–2027: An IRDiRC Perspective. Clin Transl Sci. 2018;11(1):21-27. doi:10.1111/cts.12500
9.    Seoane-Vazquez E, Rodriguez-Monguio R, Szeinbach SL, Visaria J. Incentives for orphan drug research and development in the United States. Orphanet J Rare Dis. 2008; 3(1). doi:10.1186/1750-1172-3-33
10.    Narala SR, Saraswathi K. Application of Oxidants to the Spectrophotome tric Determination of Cephalosporins (Cefditoren Pivoxil and Cefdinir) In Formulations. Tablet. 2011; 1(200): 187-199.
11.    Patil KB, Patil NB, Patil AA. Medicinal Plants for cure Common Diseases in Shirpur (Maharashtra, India). Asian J Res Pharm Sci. 2019;9(4):273. doi:10.5958/2231-5659.2019.00043.2
12.    Hapse SA, Tarkase KN, Jadhav AS, Dongare US. Study and Evaluation of Dry Powder Inhaler- A Review. 2011;3(3):87-92.
13.    Banerjee J, Padmalatha H, Ramesh K, Chanda R. Formulation and Evaluation of Fast Dissolving Tablets of Cefdinir by Employing Solid Dispersion. 2018; 10(03): 169-174. doi:10.5958/0975-4377.2018.00026.5
14.    Article R. New Technologies in Particulate Engineering for Pulmonary Delivery of Macromolecule. 2011; 4(February): 167-174.
15.    Kumar RS, Priya BL. A Mutated Transmembrane Conductance Regulator Protein Targeted for Cystic Fibrosis – An In silico Analysis. 2017; 10(November):3697-3700. doi:10.5958/0974-360X.2017.00670.9
16.    Ramanjaneyulu K V, K VR, Rao MP. Stability indicating LC Method Development and Validation for the Simultaneous analysis of Cystic Fibrosis Drugs - Ivacaftor and Tezacaftor in Pharmaceutical Formulations. 2020;13(May):2076-2080. doi:10.5958/0974-360X.2020.00373.X
17.    Dhekale KD, Kamble RN. Development of cefdinir loaded Functionalized carbon Nanotubes dry powder Inhaler for the Treatment of cystic Fibrosis. 2021;14(July):3839-3845. doi:10.52711/0974-360X.2021.00666
18.    Dutta D, Chakraborty P. Orphan Drugs - Its pros and cons. 2009;1(2):59-66.
19.    Arjun S, Venkatesh MP, Balamuralidhara V, Kumar TMP. Expedited programs for Drug Development and Approval in USA. 2020; 13(March): 1409-1414. doi:10.5958/0974-360X.2020.00258.9

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

1.3
2021CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available